CompaniesOtherNews brief

Taiji Group Unit Gains Approval for Butorphanol Tartrate Injection

Published: 10 August 2026 at 17:11Updated: 10 August 2026 at 17:57By 24TopNews Editorial Desk

Taiji Group announced on August 10 that its controlling subsidiary Southwest Pharmaceutical Co. , Ltd. had received a Drug Registration Certificate from the National Medical Products Administration for Butorphanol Tartrate Injection. The drug is classified as a Class II psychotropic substance under the Regulations on the Administration of Narcotic Drugs and Psychotropic Substances, and is indicated for the treatment of various cancer pain and postoperative pain.